1. Pink Sheet

Vertex Rejects England’s Orkambi Offer

 
• By Francesca Bruce

Vertex has rejected the “final offer” put forward by the National Health Service in England for its cystic fibrosis drugs, including Orkambi. The company’s chief executive wants a meeting with the head of the NHS.

Form close up, fountain pen and rejected stamped on a document. Soft focus.
Vertex has said no to the NHS's final offer for its cystic fibrosis drugs

Vertex has rejected the counter reimbursement offer the National Health Service in England has put forward for the company’s cystic fibrosis drugs, including the high-profile combination precision medicine, Orkambi (ivacaftor/lumacaftor). The offer is unacceptable and threatens the company’s ability to invest in R&D and works towards a cure, says Vertex.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

UK MHRA Tackles Staff Burnout As It Eliminates Filings Backlog

 
• By Vibha Sharma

Efforts by the medicines regulator, the MHRA, to clear all backlogs relating to its statutory functions and maintaining predictable review timeframes have put pressure on its staff.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 
• By Eliza Slawther

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.